# Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)

> **NCT01857115** · PHASE1,PHASE2 · COMPLETED · sponsor: **European Myeloma Network B.V.** · enrollment: 63 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01857115
- **Lead sponsor:** European Myeloma Network B.V.
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2013-11
- **Final completion:** 2024-09-01
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2024-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01857115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01857115, "Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01857115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*